References

Asthma & Immunology. Addressing health disparities in food allergy: a position statement of the AAAAI prior authorization task force

10.1016/j.jaci.2024.10.008 · 2025 · External reference

Racial, ethnic, and socioeconomic differences in food allergies in the US

10.1001/jamanetworkopen.2023.18162 · 2023 · External reference

Health disparities in pediatric food allergy

10.1016/j.anai.2022.04.022 · 2022 · External reference

Feast for thought: a comprehensive review of food allergy 2021-2023

10.1016/j.jaci.2023.11.918 · 2024 · External reference

Food allergy across the globe

10.1016/j.jaci.2021.10.018 · 2021 · External reference

Food insecurity in children and adults with food allergies

10.1016/j.anai.2022.08.012 · 2022 · External reference

The natural history of food allergy

10.1016/j.jaip.2015.11.024 · 2016 · External reference

Biomarkers of diagnosis and resolution of food allergy

2020 · External reference

Encouraging trends in peanut allergy prevention: real-world impact of prevention guidelines available

10.1542/peds.2025-072593 · 2025 · External reference

Prevalence and characteristics of accidental ingestions among pediatric food allergy patients

10.1016/j.jaip.2024.08.006 · 2024 · External reference

Mental health risks in children with food allergies: a population-based comparison of food allergies with other chronic conditions

10.1007/s00431-025-06316-0 · 2025 · External reference

Mechanisms of food allergy

10.1016/j.jaci.2017.11.005 · 2018 · External reference

New approaches in childhood IgE-mediated food allergy treatment

10.1097/aci.0000000000001058 · 2025 · External reference

Navigating the landscape of food allergies: insights and perspectives from the AMCP market insights program

2024 · External reference

Updates in food allergen immunotherapy

10.1097/mop.0000000000001272 · 2023 · External reference

Cost-effectiveness of oral immunotherapy for egg allergy according to age of therapy commencement

10.1016/j.jaip.2024.12.005 · 2025 · External reference

Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis

10.1001/jamanetworkopen.2019.3242 · 2019 · External reference

Shared decision-making in food allergy: navigating an exciting era

2024 · External reference

Viewing pediatric food oral immunotherapy through an ethical lens — a narrative systematic review

10.1016/j.jaip.2023.03.024 · 2023 · External reference

Goldilocks zone: allergists’ perceptions of family anxiety and investment in food allergy oral immunotherapy

2025 · External reference

Long-term outcome of peanut oral immunotherapy — real-life experience

10.1111/pai.12914 · 2018 · External reference

Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients

10.1016/j.jaip.2018.05.023 · 2019 · External reference

Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomized placebo-controlled study

10.1016/s0140-6736(21)02390-4 · 2022 · External reference

Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomized, double-blind, placebo-controlled, phase 2 study

10.1016/s0140-6736(19)31793-3 · 2019 · External reference

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

10.1016/s0140-6736(19)30420-9 · 2019 · External reference

Oral immunotherapy and risk of eosinophilic esophagitis in children: 15 years’ experience

10.1097/mpg.0000000000003631 · 2023 · External reference

Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study

10.1016/j.jaip.2020.12.029 · 2021 · External reference

Peanut oral immunotherapy using 30 mg and 300 mg maintenance doses

2025 · External reference

Unresolved reference

2024 · External reference

Allergen-specific IgE is a stronger predictor of remission following peanut oral immunotherapy than age in children aged 1-10 years

10.1111/all.16451 · 2025 · External reference

Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis

10.1016/j.anai.2014.08.004 · 2014 · External reference

Sublingual and patch immunotherapy for food allergy

10.1016/j.iac.2019.09.008 · 2020 · External reference

The use of grocery-sourced real-food solutions in sublingual immunotherapy for food allergies

10.1016/j.anai.2025.03.001 · 2025 · External reference

Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: a randomized, placebo-controlled trial

10.1016/j.jaci.2023.08.032 · 2024 · External reference

Peanut component-specific IgE and IgG4 are modulated by sublingual immunotherapy and are associated with remission in 1-4-year-old children

2025 · External reference

The safety and efficacy of sublingual and oral immunotherapy for milk allergy

10.1016/j.jaci.2011.10.023 · 2012 · External reference

Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy

10.1056/nejmoa2212895 · 2023 · External reference

Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial

10.1001/jama.2019.1113 · 2019 · External reference

Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis

10.2500/aap.2021.42.210028 · 2021 · External reference

Intralymphatic immunotherapy for peanut allergy: a pilot study (abstract)

10.1016/j.jaci.2018.12.780 · 2019 · External reference

Development of a subcutaneous immunotherapy (SCIT) with a modified peanut extract formulation for the treatment of peanut allergy

2019 · External reference

Safety and immunopharmacology of ASP0892 in adults or adolescents with peanut allergy: two randomized trials

2023 · External reference

Omalizumab for the treatment of multiple food allergies

10.1056/nejmoa2312382 · 2024 · External reference

Biologics in food allergies: emerging therapies

10.1016/j.iac.2024.07.004 · 2024 · External reference

Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways

10.1111/imr.13380 · 2024 · External reference

A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients

10.1016/j.jaci.2013.09.046 · 2013 · External reference

Introduction of allergenic foods after treatment with omalizumab

10.1016/j.jaci.2025.05.014 · 2025 · External reference

Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab

10.1016/j.jaip.2018.09.015 · 2019 · External reference

Omalizumab as an adjuvant in food allergen immunotherapy

10.1097/aci.0000000000000736 · 2021 · External reference

Efficacy and safety of ligelizumab in chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials

10.1007/s40261-025-01436-9 · 2025 · External reference

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms

10.1172/jci157765 · 2022 · External reference

New evidence in food allergies treatment

10.1097/aci.0000000000000999 · 2024 · External reference

Efficacy and safety of dupilumab in children with peanut allergy: a multicenter, open-label, phase II study

10.1111/all.16404 · 2025 · External reference

Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis

10.1016/j.anai.2025.07.023 · 2025 · External reference

Dupilumab as an adjunct to oral immunotherapy in pediatric patients with peanut allergy

10.1111/all.16420 · 2025 · External reference

Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

10.1172/jci.insight.131347 · 2019 · External reference

Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review

10.1016/j.anai.2025.04.012 · 2025 · External reference

Clinical Study Using Biologics to Improve Multi-OIT Outcomes (COMBINE) — ClinicalTrials.gov identifier NCT03679676; trial record (protocol/arms includes sequential omalizumab → dupilumab + mOIT)

2018 · External reference

JAK1 inhibition with abrocitinib decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy

2023 · External reference

Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy

10.1016/j.jaci.2017.12.987 · 2018 · External reference

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis

10.1172/jci172335 · 2023 · External reference

Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33

10.1016/j.jaci.2017.02.046 · 2018 · External reference

A mouse model of the LEAP study reveals a role for CTLA-4 in preventing peanut allergy induced by environmental peanut exposure

10.1016/j.jaci.2022.02.024 · 2022 · External reference

A mixture of four probiotic strains (Probiatop®) mitigates food allergy to ovalbumin in mice

2024 · External reference

Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial

10.1016/s2352-4642(22)00006-2 · 2022 · External reference

Fecal microbiota transplantation alleviates food allergy in neonatal mice via the PD-1/PD-L1 pathway and change of the microbiota composition

10.1016/j.waojou.2024.100969 · 2024 · External reference

Use of a liver-targeting nanoparticle platform to intervene in peanut-induced anaphylaxis through delivery of an Ara h2 T-cell epitope

10.1016/j.nantod.2021.101370 · 2022 · External reference

Two-year post-treatment outcomes following peanut oral immunotherapy in the probiotic and peanut oral Immunotherapy-003 long-term (PPOIT-003LT) study

10.1111/all.16262 · 2024 · External reference

Racial and ethnic representation in food allergen immunotherapy trial participants: a systematic review

10.1001/jamanetworkopen.2024.32710 · 2024 · External reference